Compare Twist Bioscience Corp (TWST) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs US Bancorp — how do they compare? Twist Bioscience Corp trades at $158.2 (market cap $10.32B), while US Bancorp trades at $57.18 (market cap $87.52B). The key difference: US Bancorp is far larger — about 8.5× Twist Bioscience Corp's market cap, and US Bancorp pays a 3.85% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and US Bancorp for 97 Days on average.
| TWST | USB | |
|---|---|---|
Market Cap | $10.32B | $87.52B |
Volume | 5,894,998 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $205.00 | $65.42 |
52-Week Low | $25.45 | $45.28 |
Typical Hold Time | 27 Days | 97 Days |
Enterprise Value | $10.24B | $117.01B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
U.S. Bancorp (USB) trades at $57.03, down 0.45% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.35 exceeding expectations by 5.5%. Revenue growth accelerated to $28.54B in 2025 with net income margin improving to 27.61%. Analyst consensus remains positive with 51% buy ratings and $69.94 price target representing 23% upside potential.
USB presents a value opportunity with attractive valuation multiples (P/E 11.21, P/B 1.44) and dividend yield of 3.8%. Near-term risks include technical weakness and regulatory uncertainties, but strong fee revenue growth and capital markets performance support the bullish fundamental case. The stock offers income appeal with sustainable dividend growth and clean loan portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
